The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 96,012,792 confirmed cases of COVID-19, including 2,075,870 deaths (as of January 22, 2021). Due to the pandemic, companies have scaled up R&D efforts to develop a vaccine and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. Due to the increase in research activities, both the availability of funding for research and the demand for and manufacturing of cell-based assay products are expected to grow.
The players operating in the market are altering their long-term and short-term growth strategies by tapping into opportunities prevalent in the research market by developing innovative products to combat the pandemic. The increased demand for research on COVID-19 has created a large scope for cell-based 45 assays in viral infection research, vaccine development, and overall drug discovery for both researchers and laboratories.
Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
Currently, a number of vaccines or antiviral drugs for COVID-19 have been approved or are under development, and patients are currently treated symptomatically. For both vaccines and therapeutics, the antibodies produced are tested for their functional efficacy to neutralize the target virus. Cell-based assays are employed to shorten the time and increase the throughput needed for these assays. This has significantly increased the demand for cell-based assays to provide an early indication of the toxicity characteristics of the drug candidates.
The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market. However, the growth of the market is likely to be restrained by factors such as the high cost of instruments, restrictions on reagent use, and the lack of infrastructure for cell-based research in emerging economies.
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period.
By application, the drug discovery segment accounted for the largest share of the cell-based assays market in 2019.
Based on application, the cell-based assays market is categorized into drug discovery, basic research, and other applications. The drug discovery application segment dominated the market in 2019. The large share of the drug discovery segment can be attributed to increasing R&D investments, technological innovations in supportive processes, the introduction of new drugs, and the growing number of CROs providing drug discovery services.
To know about the assumptions considered for the study, Request a Sample Pages
By end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the cell-based assays market in 2019.
Based on end users, the cell death assays market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes. Pharmaceutical & biotechnology companies dominated the market in 2019. The large share of this segment can be attributed to the increase in R&D expenditure, the growing number of drug discovery projects, and the adoption of strategic approaches such as collaborations to develop drug candidates.
North America accounted for the largest share of the cell death assays market in 2019.
In 2019, North America accounted for the largest share of the cell death assays market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, and the rapid adoption of advanced technologies in the region.
Key Market Players
Danaher Corporation (US), Thermo Fisher Scientific (US), Merck KGaA (Germany), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Promega Corporation (US), Charles River Laboratories (US), Lonza (Switzerland), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US) are the prominent players operating in the cell-based assays market.
Recent Developments
- In 2020, Danaher Corporation (US) launched ImageXpress Micro-confocal High-content Imaging System.
- In 2020, Thermo Fisher Scientific (US) acquired Phitonex, Inc. (US). The acquisition of spectral dye platform manufacturer Phitonex will enable Thermo Fisher to offer greater flow cytometry and imaging multiplexing capabilities in protein and cell analysis research.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=119917269
